Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[D-penicillamine--a retrospective view].

K Miehlke1

  • 1Rheumaklinik II, Wiesbaden.

Zeitschrift Fur Rheumatologie
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

D-penicillamine, discovered in 1943, is a disease-modifying drug for rheumatoid arthritis. Its efficacy and adverse effects in treatment are well-established since the 1960s.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Thoughts of a physician about the future of our health care system].

Der Internist·2000
Same author

[Anti-rheumatic agents: when--which ones?].

Verhandlungen der Deutschen Gesellschaft fur Innere Medizin·1990
Same author

[Plasma and tissue concentrations of biphenylacetic acid following 1 week oral fenbufen medication and topical administration of Felbinac gel on the knee joint].

Zeitschrift fur Rheumatologie·1989
Same author

[Drug therapy and prevention of arthrosis].

Der Internist·1989
Same author

[Drug treatment and prevention of arthrosis].

Verhandlungen der Deutschen Gesellschaft fur Innere Medizin·1989
Same author

Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma.

Rheumatology international·1987

Area of Science:

  • Pharmacology
  • Rheumatology
  • Drug Development

Context:

  • D-penicillamine, a chelating agent, was first synthesized in 1943.
  • Its therapeutic application for rheumatoid arthritis commenced in the early 1960s.
  • Extensive clinical experience has elucidated its pharmacological profile and side effects.

Purpose:

  • To review the established role of D-penicillamine in rheumatoid arthritis management.
  • To highlight its classification as a disease-modifying antirheumatic drug (DMARD).
  • To contextualize its therapeutic significance alongside other established treatments like gold compounds.

Summary:

  • D-penicillamine is recognized for its disease-modifying properties in rheumatoid arthritis.
  • Its long-standing use has provided a comprehensive understanding of its benefits and risks.

Related Experiment Videos

  • It is considered comparable in efficacy to gold salts for rheumatoid arthritis treatment.

    • Impact:

    • D-penicillamine remains a significant therapeutic option in rheumatology.
    • Understanding its historical context informs current treatment strategies.
    • This knowledge aids in managing patient expectations and monitoring for adverse events.